FDA
-
-
-
-
-
-
-
CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates
-
-
-
-
-
-
-
CG Oncology Announces New Board Member and Board Transition
-
-
-
-
-
-
-
CG Oncology Continues to Demonstrate Best-in-Disease Durability and Tolerability in BOND-003 Cohort C; Additional 12 Patients in Complete Response at 24 Months
-
-
-
-
-
-
-
CG Oncology (CGON) Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec
-
-
-
-
-
-
-
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates
-
-
-
-
-
-
-
Goldman Sachs Reiterates Buy Rating on CG Oncology (CGON)
-
-
-
-
-
-
-
CG Oncology (CGON) Announces Proposed IPO
328,553 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

